Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Administration of mucolytic solution before upper endoscopy - double-blind, monocentric, randomized study

M. Stepan, P. Falt, B. Pipek, P. Fojtik, M. Hanousek, M. Hill, O. Urban

. 2023 ; 167 (1) : 69-73. [pub] 20210622

Jazyk angličtina Země Česko

Typ dokumentu randomizované kontrolované studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23002216

AIMS: Sufficient visibility of the mucosa during upper endoscopy is crucial for successful diagnosis, especially for early neoplastic lesions. Data documenting the effect of administration of mucolytic solution prior to gastroscopy in order to improve mucosal visibility are limited in Europe. The aim of the study was to assess the score of mucosal visibility in the upper gastrointestinal tract after administration of the mucolytic solution defined by us. PATIENTS AND METHODS: This is a monocentric, double-blind, randomized study involving 134 patients indicated for diagnostic upper endoscopy. Patients were randomly assigned to one of three arms, with mucolytic solution (100 mL water + 400 mg N-acetylcysteine + 20 mg simethicone), without the solution , and with 100 mL pure water. During the examination, 11 photographs were taken in defined areas. The visibility score was given by the sum of the score 0-5 from 5 defined localities evaluated by a blinded endoscopist and subsequently by two blinded endoscopists. Other parameters monitored were examination time and a semiquantitative evaluation of residual gastric fluid. RESULTS: The basic characteristics of the group (sex, age, indications for examination) were comparable between arms. The visibility score was similar in all arms - 17.4 ± 1.9 vs. 17.0 ± 2.0 vs. 17.6 ± 1.8 (P=0.32). The examination time and the amount of residual fluid in the stomach were comparable in all arms. CONCLUSIONS: Administration of the mucolytic solution in our study did not increase the mucosal visibility score in the esophagus, stomach and duodenum. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02967094.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002216
003      
CZ-PrNML
005      
20230517134549.0
007      
ta
008      
230406s2023 xr a f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2021.038 $2 doi
035    __
$a (PubMed)34158672
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Štěpán, Michal, $u Digestive Diseases Center, Vitkovice Hospital, Ostrava, Czech Republic $u Department of Internal Medicine II - Gastroenterology and Hepatology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1984- $7 xx0224386
245    10
$a Administration of mucolytic solution before upper endoscopy - double-blind, monocentric, randomized study / $c M. Stepan, P. Falt, B. Pipek, P. Fojtik, M. Hanousek, M. Hill, O. Urban
520    9_
$a AIMS: Sufficient visibility of the mucosa during upper endoscopy is crucial for successful diagnosis, especially for early neoplastic lesions. Data documenting the effect of administration of mucolytic solution prior to gastroscopy in order to improve mucosal visibility are limited in Europe. The aim of the study was to assess the score of mucosal visibility in the upper gastrointestinal tract after administration of the mucolytic solution defined by us. PATIENTS AND METHODS: This is a monocentric, double-blind, randomized study involving 134 patients indicated for diagnostic upper endoscopy. Patients were randomly assigned to one of three arms, with mucolytic solution (100 mL water + 400 mg N-acetylcysteine + 20 mg simethicone), without the solution , and with 100 mL pure water. During the examination, 11 photographs were taken in defined areas. The visibility score was given by the sum of the score 0-5 from 5 defined localities evaluated by a blinded endoscopist and subsequently by two blinded endoscopists. Other parameters monitored were examination time and a semiquantitative evaluation of residual gastric fluid. RESULTS: The basic characteristics of the group (sex, age, indications for examination) were comparable between arms. The visibility score was similar in all arms - 17.4 ± 1.9 vs. 17.0 ± 2.0 vs. 17.6 ± 1.8 (P=0.32). The examination time and the amount of residual fluid in the stomach were comparable in all arms. CONCLUSIONS: Administration of the mucolytic solution in our study did not increase the mucosal visibility score in the esophagus, stomach and duodenum. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02967094.
650    _2
$a lidé $7 D006801
650    12
$a expektorancia $7 D005100
650    12
$a gastrointestinální endoskopie $7 D016099
650    _2
$a acetylcystein $7 D000111
650    _2
$a gastroskopie $7 D005773
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a voda $7 D014867
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Falt, Přemysl, $u Department of Internal Medicine II - Gastroenterology and Hepatology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1981- $7 xx0149631
700    1_
$a Pipek, Barbora $u Digestive Diseases Center, Vitkovice Hospital, Ostrava, Czech Republic $u Department of Internal Medicine II - Gastroenterology and Hepatology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $7 xx0224384
700    1_
$a Fojtík, Petr $u Digestive Diseases Center, Vitkovice Hospital, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $7 xx0105601
700    1_
$a Hanousek, Martin $u Digestive Diseases Center, Vitkovice Hospital, Ostrava, Czech Republic $7 xx0258702
700    1_
$a Hill, Martin, $u Institute of Endocrinology, Prague, Czech Republic $d 1962- $7 mzk2005304431
700    1_
$a Urban, Ondřej, $u Department of Internal Medicine II - Gastroenterology and Hepatology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1965- $7 stk2008428564
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 167, č. 1 (2023), s. 69-73
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34158672 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20230406 $b ABA008
991    __
$a 20230517134544 $b ABA008
999    __
$a ok $b bmc $g 1933544 $s 1188422
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 167 $c 1 $d 69-73 $e 20210622 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK198 $a Pubmed-20230406

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...